Dermal Safety Trial of Ztilido (Lidocaine patch 1.8%) for the Treatment of Postherpetic Neuralgia

Trial Profile

Dermal Safety Trial of Ztilido (Lidocaine patch 1.8%) for the Treatment of Postherpetic Neuralgia

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Postherpetic neuralgia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Aug 2014 This trial is expected to be completed by November 2014, and a New Drug Application is expected to be filed in the first quarter of 2015, according to a Scilex Pharmaceuticals media release.
    • 11 Aug 2014 Status changed from recruiting to active, no longer recruiting, according to a Scilex Pharmaceuticals media release.
    • 14 Jul 2014 Status changed from planning to recruiting according to the Scilex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top